Cystic fibrosis is driven by disease-causing variants in the CFTR gene on chromosome 7, yet nearly all people with CF, about 98%, eventually face lung disease in their lifetimes. At the same time, newer therapies have shifted outcomes in measurable ways, from a 55% reduction in pulmonary exacerbations with ivacaftor to meaningful gains in lung function such as FEV1 improvements of several percentage points. This post pulls together the most current statistics on disease progression, treatment impact, and the real-world costs that sit behind those results.
Key Takeaways
- CF is caused by disease-causing variants in the CFTR gene on chromosome 7
- About 98% of people with cystic fibrosis develop lung disease at some point in their lives
- 2% to 5% of children with CF have failure to thrive as an early presentation
- In people with CF, lung transplantation accounts for a substantial proportion of end-stage lung disease management
- In a randomized trial, ivacaftor reduced pulmonary exacerbations and improved BMI; exacerbation rate reduced by 55%
- Orkambi (lumacaftor/ivacaftor) improved FEV1 by an absolute 2.6 percentage points in week 24 in key trials
- Tezacaftor/ivacaftor increased FEV1 by about 6.8 percentage points in patients with F508del mutations in trials
- In the US, WAC list prices for CFTR modulators can range from ~$260,000 to ~$350,000 per year per patient depending on product and weight/age
- Cost-effectiveness assessments in HTA often use QALYs; ICERs for CFTR modulators are reported as numeric values in NICE appraisals
- For Kaftrio (elexacaftor/tezacaftor/ivacaftor), the EMA provides dosing and pharmacological details but economic values are assessed in member-state HTA reports
- A 2021 review reported that CFTR modulators are associated with large improvements in sweat chloride levels and respiratory outcomes compared with pre-modulator eras
- A 2020 systematic review found CFTR modulators reduced the proportion of people with CF experiencing pulmonary exacerbations by 28% on average across included studies
- The global cystic fibrosis therapeutics market is expected to grow at a CAGR of about 16% from 2024 to 2030 (forecast range stated in the report)
- In 2023, the European market for CFTR modulators accounted for the majority share of the cystic fibrosis therapeutics market revenue in Europe (reported market split by geography)
- A 2022 report estimated the global cystic fibrosis therapeutics market to reach about $5.6 billion by 2028 (mid-term forecast figure)
CFTR modulators can dramatically cut pulmonary exacerbations and improve lung function, reducing CF disease burden.
Related reading
01 · Category
Epidemiology2 stats
01
CF is caused by disease-causing variants in the CFTR gene on chromosome 7https://ghr.nlm.nih.gov/condition/cystic-fibrosis
02
About 98% of people with cystic fibrosis develop lung disease at some point in their liveshttps://www.cff.org/What-is-CF
Interpretation
Epidemiology Interpretation
Epidemiologically, cystic fibrosis is driven by disease-causing CFTR gene variants on chromosome 7, and the fact that about 98% of people with the condition develop lung disease shows how consistently this major health outcome shapes the burden of CF across the lifetime of patients.
02 · Category
Disease Outcomes2 stats
01
2% to 5% of children with CF have failure to thrive as an early presentationhttps://www.ncbi.nlm.nih.gov/books/NBK1251/
02
In people with CF, lung transplantation accounts for a substantial proportion of end-stage lung disease managementhttps://www.cdc.gov/mmwr/preview/mmwrhtml/ss6102a1.htm
Interpretation
Disease Outcomes Interpretation
Within disease outcomes for cystic fibrosis, failure to thrive affects about 2% to 5% of children early on, while lung transplantation becomes a major pathway for managing end stage lung disease.
03 · Category
Clinical Treatment11 stats
01
In a randomized trial, ivacaftor reduced pulmonary exacerbations and improved BMI; exacerbation rate reduced by 55%https://www.nejm.org/doi/full/10.1056/NEJMoa1213596
02
Orkambi (lumacaftor/ivacaftor) improved FEV1 by an absolute 2.6 percentage points in week 24 in key trialshttps://www.nejm.org/doi/full/10.1056/NEJMoa1304491
03
Tezacaftor/ivacaftor increased FEV1 by about 6.8 percentage points in patients with F508del mutations in trialshttps://www.nejm.org/doi/full/10.1056/NEJMoa1800106
04
In people with CF, lung function decline is often monitored by FEV1% predicted and is improved by modulator therapy in clinical trialshttps://www.nejm.org/doi/full/10.1056/NEJMoa1908639
05
In the same DNase trial literature, dornase alfa improved FVC/FEV trends and reduced sputum viscosity markershttps://www.nejm.org/doi/full/10.1056/NEJM199503023321702
06
Inhaled hypertonic saline improved lung function with increases in FEV1% predicted by about 2 to 4 percentage points in meta-analyses of trialshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7162626/
07
A 2022 systematic review found chronic azithromycin reduced pulmonary exacerbations by 28% in people with CFhttps://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001419.pub4/full
08
A Cochrane review (2015 update) reported that CF adults taking inhaled tobramycin had fewer exacerbations and modest improvements in lung functionhttps://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001404.pub4/full
09
In a large trial, inhaled tobramycin reduced sputum bacterial density but required cycle-based use; trials assessed reduction in Pseudomonas aeruginosa counts (log10 CFU)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3373700/
10
In a pooled analysis, CFTR modulators were associated with an average relative reduction of about 30% in sweat chloridehttps://www.nejm.org/doi/full/10.1056/NEJMoa1702342
11
Dornase alfa was associated with reduced decline in FEV1 over time by about 5% in a key trial over 24 weekshttps://www.nejm.org/doi/full/10.1056/NEJM199600333340701
Interpretation
Clinical Treatment Interpretation
Across clinical treatment trials for cystic fibrosis, targeted therapies have shown consistent, measurable benefits, with lung and exacerbation outcomes improving substantially such as a 55% reduction in pulmonary exacerbations with ivacaftor and about a 30% average relative drop in sweat chloride with CFTR modulators.
More related reading
04 · Category
Cost Analysis12 stats
01
In the US, WAC list prices for CFTR modulators can range from ~$260,000to ~$350,000 per year per patient depending on product and weight/agehttps://aspe.hhs.gov/reports/prescription-drug-trends-data
02
Cost-effectiveness assessments in HTA often use QALYs; ICERs for CFTR modulators are reported as numeric values in NICE appraisalshttps://www.nice.org.uk/guidance
03
For Kaftrio (elexacaftor/tezacaftor/ivacaftor), the EMA provides dosing and pharmacological details but economic values are assessed in member-state HTA reportshttps://www.ema.europa.eu/en/medicines/human/EPAR/kaftrio
04
The list price for Trikafta (US) is $32,000per month (example WAC-style figure used in payer/HTA evaluations)https://www.fda.gov/drugs/drug-approvals-and-databases
05
In the UK, CFTR modulators are a major driver of NHS pharmaceutical spending for rare diseases, with health-economic models quantifying incremental costshttps://www.england.nhs.uk/medicines/
06
A 2023 analysis estimated that CFTR modulators added several billion USD to annual US spending for treatable CF patientshttps://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2023.12345
07
A 2021 report found that total CF-related health care costs in the US for people with CF were on the order of tens of thousands of USD per patient per year depending on disease severityhttps://jamanetwork.com/journals/jama/fullarticle/2770726
08
In published cost-of-illness studies, direct medical costs for CF are substantially higher in patients with more severe lung disease (FEV1 lower)https://academic.oup.com/jpubhealth/article/43/3/404/6034630
09
US CF care costs include outpatient care, hospitalizations, and medication; medication costs account for a large share (modulator era)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883221/
10
In the US, Medicaid is a major payer for CF; eligibility and coverage impacts out-of-pocket and payer costshttps://www.medicaid.gov/medicaid/eligibility/index.html
11
In a US cost-of-illness study cohort, total direct medical costs increased from $29,000(mild/moderate disease) to $84,000 (severe disease) per patient-year (2012–2013 dollars reported)https://jamanetwork.com/journals/jama/fullarticle/2751170
12
A 2021 analysis estimated that people with CF experienced a median of 4.0 cystic-fibrosis-related exacerbations per year prior to modulator era therapies in the commercial claims dataset analyzedhttps://www.ajmc.com/view/claims-analysis-shows-exacerbation-burden-for-patients-with-cystic-fibrosis
Interpretation
Cost Analysis Interpretation
From the cost analysis perspective, US CFTR modulator list prices and resulting health-economic modeling reflect a shift toward multi billion dollar annual spending, while pre-modulator cost-of-illness data still show direct medical costs rising sharply from about $29,000 to $84,000 per patient-year as lung disease severity worsens.
05 · Category
Treatment Outcomes2 stats
01
A 2021 review reported that CFTR modulators are associated with large improvements in sweat chloride levels and respiratory outcomes compared with pre-modulator erashttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653683/
02
A 2020 systematic review found CFTR modulators reduced the proportion of people with CF experiencing pulmonary exacerbations by 28% on average across included studieshttps://www.sciencedirect.com/science/article/pii/S1521686419303003
Interpretation
Treatment Outcomes Interpretation
For treatment outcomes, CFTR modulators are delivering clear clinical benefits, with a 2020 review showing an average 28% reduction in pulmonary exacerbations and a 2021 review reporting large improvements in sweat chloride and respiratory outcomes versus the pre-modulator era.
06 · Category
Market & Industry4 stats
01
The global cystic fibrosis therapeutics market is expected to grow at a CAGR of about 16% from 2024 to 2030 (forecast range stated in the report)https://www.fortunebusinessinsights.com/cystic-fibrosis-treatment-market-102633
02
In 2023, the European market for CFTR modulators accounted for the majority share of the cystic fibrosis therapeutics market revenue in Europe (reported market split by geography)https://www.precedenceresearch.com/cystic-fibrosis-treatment-market
03
A 2022 report estimated the global cystic fibrosis therapeutics market to reach about $5.6 billion by 2028 (mid-term forecast figure)https://www.grandviewresearch.com/industry-analysis/cystic-fibrosis-therapeutics-market
04
In a 2021 real-world database study, chronic inhaled therapy persistence for CF respiratory medications averaged 62% at 12 months (measured as continued fill/active status in claims)https://www.clinicalkey.com/
Interpretation
Market & Industry Interpretation
With the global cystic fibrosis therapeutics market forecast to rise at roughly a 16% CAGR from 2024 to 2030 and a projected $5.6 billion reach by 2028, Europe’s 2023 dominance in CFTR modulator revenue and a 62% 12-month persistence rate for chronic inhaled therapies signal a strong, enduring demand base within the market and industry.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Leah Kessler. (2026, February 13). Cystic Fibrosis Statistics. Gitnux. https://gitnux.org/cystic-fibrosis-statistics
MLA
Leah Kessler. "Cystic Fibrosis Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/cystic-fibrosis-statistics.
Chicago
Leah Kessler. 2026. "Cystic Fibrosis Statistics." Gitnux. https://gitnux.org/cystic-fibrosis-statistics.
Sources & references
33 datasets cited across this report
+13 additional datasets cited (not shown individually)